PTC Therapeutics Provides Update on German pricing and Reimbursement Process for Translarna™ (ataluren)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Wedbush Downgrades PTC Therapeutics (PTCT) to Neutral
March 1, 2016 7:29 AM ESTWedbush downgraded PTC Therapeutics (NASDAQ: PTCT) from Outperform to Neutral with a price target of $11.00 (from $27.00), saying lower Translarna estimates shift risk/reward.
Analyst Heather Behanna commented, "Though we still believe Translarna has a good chance of full EU approval, we are... More
Cowen Downgrades PTC Therapeutics (PTCT) to Market Perform
March 1, 2016 7:27 AM ESTCowen downgraded PTC Therapeutics (NASDAQ: PTCT) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.
Shares of PTC Therapeutics closed at $7.98 yesterday.
... MoreGermany Seeks PTC Therapeutics (PTCT) Translarna Discount - Oppenheimer
February 29, 2016 9:32 AM ESTOppenheimer analyst, Christopher Marai, quantified PTC Therapeutics' (NASDAQ: PTCT) lost opportunity from a failed arbitration process in Germany. More detail will be on today's earnings call after the close but the analyst defines the scope to keep in context. No change yet to the Outperform rating.
PTC announced Friday that an arbitration process with German Federal Association of the Statutory Health Insurances (GKV-SV) concluded with an unacceptable decision. Authorities may have suggested as much as a 65% price reduction, though this is unconfirmed. PTCT is considering removing the drug from the German market;... More
